Search clinical trials for: TC-5214 Placebo

Total 53783 results

AstraZeneca

Completed

A Study of Single and Multiple Ascending Doses of TC-5214 in Japanese Healthy Elderly Male and Female Volunteers

Healthy

Japan
Targacept Inc.

Terminated

TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension

Refractory Hypertension

United States
AstraZeneca

Completed

A Study to Assess Safety and Tolerability as Well as Absorption and Excretion of TC-5214 in Medically Stable Elderly Subjects

Elderly Subjects 65 Years and Older, Healthy or With a Stable Disease and Treatment.

Sweden
Targacept Inc.

Completed

Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder

Overactive Bladder

United States
Atacama Therapeutics

Completed

Exploratory Study to Assess the Efficacy and Safety of TC-5214 in the Treatment of Subjects With Palmar Hyperhidrosis

Palmar Hyperhidrosis

United States
AstraZeneca

Completed

To Investigate Safety, Tolerability and Pharmacokinetics of TC-5214 in Healthy Male Japanese Subjects

Healthy
AstraZeneca

Completed

To Investigate the Safety and Tolerability of TC-5214 Following Oral Administration of Multiple Doses for up to 8 Days

Healthy

United States
AstraZeneca

Completed

Study in Healthy Subjects to Measure the Effects of Food on the Pharmacokinetics of TC-5214 (TC-5214)

Healthy Subjects

United States
AstraZeneca
Targacept Inc.

Completed

A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

Depression | Major Depressive Disorder | MDD

United States, Puerto Rico
AstraZeneca
Targacept Inc.

Completed

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.

Major Depressive Disorder

Croatia, Brazil, Bulgaria, France, Poland, Russian Federation, South Africa, Hungary, Romania, Ukraine, Argentina, Chile, Slovakia, Colombia, Germany, Serbia, Spain
AstraZeneca

Completed

To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal Function

Renal Impairment | Healthy Volunteers | Pharmacokinetics | Patients

United States
AstraZeneca
Targacept Inc.

Completed

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

Depression | Major Depressive Disorder

United States, India, Puerto Rico
AstraZeneca
Targacept Inc.

Completed

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

Depression | Major Depressive Disorder

Sweden, Czech Republic, Poland, Germany, Estonia, Latvia, Lithuania, Finland, France, Hungary
AstraZeneca
Targacept Inc.

Completed

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)

Depression | Major Depressive Disorder

United States, India
AstraZeneca

Terminated

To Determine Blood Pressure Interaction Between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors) in Patients With Chronic Hypertension

Chronic Hypertension

United Kingdom, Germany, United States
Atacama Therapeutics

Active, not recruiting

Clinical Study to Assess the Efficacy and Safety of AT-5214 in the Treatment of Subjects With Palmar Hyperhidrosis

Hyperhidrosis | Palmar Hyperhidrosis

United States
AstraZeneca

Withdrawn

Study in Healthy Recreational Polydrug Users to Measure the Abuse Potential of TC-5214 (TC-5214)

Healthy | Drug Abuse
Targacept Inc.

Completed

Safety & Efficacy of TC-5619 in Adults With Inattentive-predominant Attention Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

United States
Targacept Inc.

Completed

Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia

Schizophrenia | Cognitive Dysfunction | Negative Symptoms

United States, Serbia, Ukraine, Russian Federation, Hungary, Romania
Targacept Inc.

Completed

Study Evaluating the Effect of TC-6499 on Gastric Emptying Time in Diabetic Subjects With Gastroparesis

Gastroparesis

United States
Targacept Inc.

Completed

Proof-of-Principle Study of TC-6499 in the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS)

Irritable Bowel Syndrome

United Kingdom
Targacept Inc.

Completed

TC-5619 as Augmentation Therapy to Improve Cognition in Outpatients With Cognitive Dysfunction in Schizophrenia

Schizophrenia | Cognitive Dysfunction

United States, India
Targacept Inc.

Completed

TC-6987 for the Treatment of Mild to Moderate Asthma

Asthma

United States
Targacept Inc.

Completed

Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Targacept Inc.

Completed

Multiple Ascending Dose Study of TC-5619 in Healthy Elderly Subjects and Subjects With Alzheimer's Disease

Alzheimer's Disease

United States
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)

Alzheimer Disease

United States
Targacept Inc.

Completed

Efficacy, Safety, and Tolerability of TC-5619 in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)

ADHD

United States
Dong-A ST Co., Ltd.

Recruiting

Clinical Trial to Evaluate the Efficacy and Safety of DA-5219 in Patients With Acute or Chronic Gastritis

Gastritis Acute | Gastritis Chronic

Korea, Republic of
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Phase 1 Study to Evaluate the Safety and Tolerability of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy Volunteers

Subcutaneous Fat

Australia
Bayer
TAP Pharmaceutical Products Inc.

Completed

Menorrhagia Study in Women With Treatment-resistant Menorrhagia

Menorrhagia
The University of Hong Kong

Active, not recruiting

Tai Chi-muscle Power Training for Primary School Children With Developmental Coordination Disorder

Developmental Coordination Disorder

Hong Kong
Regeneron Pharmaceuticals

Completed

Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Participants

Healthy Volunteers | Birch Pollen Allergy

Belgium
AdAlta Limited

Completed

Safety, Tolerability, PK and PD Study of AD-214 Administered to Healthy Volunteers and Patients With Interstitial Lung Disease or Chronic Kidney Disease

Chronic Kidney Diseases | Interstitial Lung Disease

Australia
AdAlta Limited

Completed

Phase 1 Safety, Tolerability, PK & PD Study of AD-214 Administered to Healthy Volunteers

Interstitial Lung Disease

Australia
Intra-Cellular Therapies, Inc.

Completed

Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of ITI-214 in Patients With Heart Failure

Heart Failure, Systolic

United States
Intra-Cellular Therapies, Inc.

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease

Parkinson Disease

United States
Anza Therapeutics, Inc.

Terminated

Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C Virus

Chronic Hepatitis C

United States
Intra-Cellular Therapies, Inc.
Laureate Institute for Brain Research, Inc.

Completed

Study of ITI-214 in Healthy Volunteers to Determine CNS Engagement

Healthy Volunteers

United States
Dong-A ST Co., Ltd.

Not yet recruiting

Pharmacokinetics and Safety Profiles After Administration of DA-5218 and Co-administration of DA-5218-R1, DA-5218-R2 and DA-5218-R3 in Healthy Adult Volunteers

Healthy

Korea, Republic of
Dong-A ST Co., Ltd.

Completed

Pharmacokinetics and Safety Profiles After Administration of DA-5211 and Co-administration of DA-5211-R1 and DA-5211-R2 in Healthy Adult Volunteers

Healthy

Korea, Republic of
MedImmune LLC

Withdrawn

A Phase 3 Trial of the Effect of Motavizumab Prophylaxis on Reduction of Serious Early Childhood Wheezing in Infants

Wheezing
Takeda
Intra-Cellular Therapies, Inc.

Terminated

Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia

Schizophrenia

United States
Dong-A ST Co., Ltd.

Not yet recruiting

Phase III Clinical Trial of DA-5212 in Patients With Functional Dyspepsia

Functional Dyspepsia

Korea, Republic of
Dong-A ST Co., Ltd.

Recruiting

A Clinical Trial to Compare the Safety, Tolerability, and PK Properties of DA-5216 and DA-5216-R and to Evaluate the Food Effect on DA-5216.

Healthy

Korea, Republic of
Memorial Health University Medical Center

Unknown

Tilmanocept vs Sulfur Colloid in Sentinel Lymph Node Biopsy

Breast Cancer | Sentinel Lymph Node Biopsy

United States
BioVentrix

Active, not recruiting

BioVentrix Revivent TC™ System Clinical Study

Ventricular Dysfunction, Left

United States, United Kingdom, Czechia, Greece
Smith & Nephew Medical (Shanghai) Ltd

Completed

TC-A Registration Study

Rheumatoid Arthritis | Avascular Necrosis | Post-traumatic Arthritis | Primary Osteoarthritis

China
Dong-A ST Co., Ltd.

Completed

Phamacokinetics and Safety Profiles of DA-5213 10mg in Healthy Subjects

Healthy

Korea, Republic of
Hospital Universitari Vall d'Hebron Research Institute
Sysmex España S.L.

Unknown

Sentinel Lymph Node Biopsy With Superparamagnetic Iron Oxide for Breast Cancer Patients After Neoadjuvant Treatment. (SENTINAC-01)

Breast Cancer

Spain
BioVentrix
Ohio State University

Completed

Clinical Study of the BioVentrix Revivent TC for the Treatment of Ischemic Cardiomyopathy (ReviventTC1)

Heart Failure

Spain

3

Subscribe